The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

Bioline Introduces HyperPAGE II Broad Range Prestained Protein Marker

Wednesday, January 18, 2012

Bioline Introduces HyperPAGE II Broad Range Prestained Protein Marker07:00 EST Wednesday, January 18, 2012 CINCINNATI (Business Wire) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the latest addition to its HyperPAGE range of prestained molecular weight protein markers. HyperPAGE II contains 9 highly purified protein bands from 10 to 250kDa prestained with different fluorescence dyes to facilitate easy identification and orientation whether performing protein electrophoresis by SDS-PAGE or Western Blotting. The protein marker is ideal to monitor efficiency in electrophoresis and transfer of proteins from gel to membrane following Western blotting, and to estimate the molecular weight of protein samples. Marco Calzavara, President at Bioline, commented, “The new HyperPAGE II prestained protein marker facilitates protein electrophoresis by offering sharp, accurate and easily identifiable bright bands as is already familiar to existing HyperPAGE customers but now also in an easier, ready-to-use format.” Richard L. Eberly, Chief Commercial Officer of Meridian Bioscience, Inc., stated, “HyperPAGE II maintains the quality and accuracy that researchers have come to expect from Bioline and demonstrates our commitment to help life science customers in the research lab, clinical diagnostic labs, diagnostic manufacturers, and biotech companies.” ABOUT MERIDIAN BIOSCIENCE, INC. Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company's shares are traded through NASDAQ's Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com. ADDITIONAL INFORMATION For more information about Bioline, please visit www.bioline.com.For more information about Meridian Life Science, Inc., please visit www.meridianlifescience.com.For more information about Meridian Bioscience, Inc., please visit www.meridianbioscience.com. Meridian Bioscience, Inc.Richard L. Eberly, Chief Commercial Officer, 513-271-3700rick.eberly@meridianbioscience.com